Organigram Holdings Inc. (NASDAQ:OGI - Free Report) - Equities researchers at Alliance Global Partners increased their FY2024 earnings per share estimates for shares of Organigram in a research report issued on Monday, December 9th. Alliance Global Partners analyst A. Grey now anticipates that the company will post earnings per share of ($0.18) for the year, up from their prior estimate of ($0.19). The consensus estimate for Organigram's current full-year earnings is ($0.21) per share. Alliance Global Partners also issued estimates for Organigram's Q4 2024 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.02) EPS.
Organigram Stock Down 1.0 %
OGI traded down $0.02 during trading on Wednesday, reaching $1.53. 395,962 shares of the company's stock were exchanged, compared to its average volume of 931,252. The company has a market capitalization of $166.10 million, a P/E ratio of -3.67 and a beta of 1.02. The business has a 50 day moving average price of $1.65 and a 200 day moving average price of $1.68. Organigram has a fifty-two week low of $1.20 and a fifty-two week high of $2.91.
Institutional Trading of Organigram
Several institutional investors have recently made changes to their positions in OGI. Toronto Dominion Bank raised its position in Organigram by 803.7% in the third quarter. Toronto Dominion Bank now owns 16,727 shares of the company's stock worth $30,000 after purchasing an additional 14,876 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new position in shares of Organigram in the 2nd quarter worth approximately $51,000. Canton Hathaway LLC lifted its position in shares of Organigram by 115.8% during the 2nd quarter. Canton Hathaway LLC now owns 41,000 shares of the company's stock worth $63,000 after buying an additional 22,000 shares during the period. Baader Bank Aktiengesellschaft boosted its stake in Organigram by 26.4% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 252,852 shares of the company's stock valued at $388,000 after buying an additional 52,852 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Organigram by 40.8% in the second quarter. Renaissance Technologies LLC now owns 816,948 shares of the company's stock valued at $1,258,000 after acquiring an additional 236,700 shares during the period. 34.63% of the stock is currently owned by institutional investors and hedge funds.
About Organigram
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Articles
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
